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The Verigene Gram-positive blood culture test (BC-GP) and the Verigene Gram-negative blood culture
test (BC-GN) identify representative Gram-positive bacteria, Gram-negative bacteria and their antimi-
crobial resistance by detecting resistance genes within 3 h. Signiﬁcant beneﬁts are anticipated due to
their rapidity and accuracy, however, their clinical utility is unproven in clinical studies. We performed a
clinical trial between July 2014 and December 2014 for hospitalized bacteremia patients. During the
intervention period (N ¼ 88), Verigene BC-GP and BC-GN was used along with conventional microbio-
logical diagnostic methods, while comparing the clinical data and outcomes with those during the
control period (N ¼ 147) (UMIN registration ID: UMIN000014399). The median duration between the
initiation of blood culture incubation and the reporting time of the Verigene system results was 21.7 h
(IQR 18.2e26.8) and the results were found in 88% of the cases by the next day after blood cultures were
obtained without discordance. The hospital-onset infection rate was higher in the control period (24% vs.
44%, p ¼ 0.002), however, no differences were seen in co-morbidities and severity between the control
and intervention periods. During the intervention period, the time of appropriate antimicrobial agents'
initiation was signiﬁcantly earlier than that in the control period (p ¼ 0.001) and most cases (90%; 79/88)
were treated with antimicrobial agents with in-vitro susceptibility for causative bacteria the day after the
blood culture was obtained. The costs for antimicrobial agents were lower in the intervention period
(3618 yen vs. 8505 yen, p ¼ 0.001). The 30-day mortality was lower in the intervention period (3% vs.
13%, p ¼ 0.019).
© 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction resistance organisms (MDROs) has led to signiﬁcant threats toInappropriate antimicrobial therapy is associated with a worse
prognosis [1] and the increasing prevalence of multidrug-ses, Department of Medicine,
Tsukuba, Ibaraki 305-8558,
3.
The JapaneseAssociation for Infectio
/).clinical practice. In most developed countries, nearly half of the
Staphylococcus aureus strains that are clinically isolated are
methicillin-resistant [2], and extended-spectrum beta-lactamase-
producing Enterobacteriaceae have been commonly detected
worldwide [3e6]. While these MDROs were classically considered
to be causative pathogens of nosocomial or healthcare-associated
infections, community-acquired MDROs are now well recognized
[7] and cause bacteremia even in previously healthy patients [8,9].usDiseases. Published by Elsevier Ltd. This is an open access article under theCC BY-NC-ND
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(AST) are crucial tools for the treatment of bacterial infections,
especially for bacteremia. However, bacterial culture requires
several days to determine the bacterial phenotypes, and the reports
are delayed over weekends or holidays due to the lack of skilled
human resources. Thus, information regarding bacterial identiﬁ-
cation or AST is generally unavailable for clinical decisions
regarding treatment for at least two days, which has previously
been reported to be the breakpoint for the prognosis of S. aureus
bacteremia [10].
The Verigene system (Nanosphere Inc., Northbrook, IL, USA) is a
rapid diagnostic instrument that employs a microarray-based,
multiplexed, automated molecular method. The Verigene Gram-
positive blood culture test (BC-GP) and Verigene Gram-negative
blood culture test (BC-GN) can identify representative Gram-
positive (GP) and Gram-negative (GN) bacteria, along with their
antimicrobial resistance, by detecting resistance genes (mecA, vanA,
vanB; BC-GP, blaCTX-M, blaIMP, blaKPC, blaNDM, blaOXA, blaVIM; BC-GN).
Both of the tests are performed directly on the blood from positive
blood culture bottles incubated without pretreatment, and report
results are available within 3 h (2.5 h with the BC-GP, 2 h with the
GC-GN).
Both the BC-GP and BC-GN have been shown to cover 82e95% of
bacteria isolated from the blood of patients with bacteremia
[11e19]. The concordance rate of the Verigene system (BC-GP, BC-
GN) with conventional microbiological methods has been re-
ported to be 92e98% for BC-GP [11e13,16,20e24] and 90e98% for
BC-GN [14,25e27]. Most of the disagreements occurred among
cases with multiple-organism bacteremia, and both of the tests
were approved by the Food and Drug Administration (FDA) in 2013
as rapid diagnostic tests for bacteremia.
Due to the their rapidity and high performance for bacterial
identiﬁcation and the prediction of antimicrobial resistance, the
potential for signiﬁcant beneﬁts has been anticipated by increasing
the rate of early administration of effective antimicrobial agents
and reducing the rate of administration of unnecessary antimi-
crobial agents [11,15,19]. However, these potential beneﬁts have not
yet been widely proven in clinical trials, and were only partially
performed for Streptococcus and Enterococcus species [28,29].
In the present study, we performed a clinical trial to investigate
the clinical utility of the Verigene tests (BC-GP and BC-GN) for the
treatment of patients with bacteremia caused by Gram-positive
and -negative bacteria.
1.1. Patients and methods
This clinical trial was performed at Tsukuba Medical Center
Hospital (TMCH, 413 beds), which is located next to the University
of Tsukuba Hospital and plays a role as a tertiary emergency
medical center in the Tsukuba district of Japan. The intervention
was prospectively performed between July 1, 2014 and December
31, 2014 after an evaluation of the reliability of the Verigene BC-GP
and BC-GN for bacterial identiﬁcation and antimicrobial resistance
prediction (Supplementary ﬁle 1), and the clinical data were
compared with those of a control period (October 1,
2012eSeptember 30, 2013). During the intervention period, written
informed consent was obtained from all patients or from their
surrogate decision-maker, as appropriate. This study was per-
formed for patients suffering from bacteremia during the acute
phase of infections, and a procedure for inclusion in emergency
situations was applied accordance with the ethical guidelines for
clinical studies indicated by the Ministry of Health, Labour and
Welfare of Japan.
(http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/hokabunya/
kenkyujigyou/i-kenkyu/).If patients or their surrogate decision-makers were unable to
provide informed consent at the time when bacteremia was diag-
nosed, the examination using the Verigene system was tentatively
performed with the results provided to each physician, and written
informed consent was ultimately obtained from patients who
survived or from their surrogate decision-maker. This study was
performed with approval from the ethics committee of TMCH
(UMIN registration ID: UMIN000014399).
The details of deﬁnitions used in current study are summarized
in Supplementary ﬁle 2.1.2. Patients
All hospitalized patients with positive blood cultures containing
GP or GN detected by the BacT/ALERT 3D system (Sysmex bio-
Merieux Co., Ltd., Tokyo, Japan) were considered and reviewed for
selection both in the intervention and the control periods. The
accuracy of BC-GP and BC-GN for multiple organisms were not
assured; therefore, we excluded patients with bacteremia caused
by more than two species of bacteria, as suspected from the Gram
staining examinations. Other exclusion criteria were 1) If only one
set of blood cultures was positive. Either one set or two sets of
blood cultures were incubated, and Staphylococcus spp. or Gram-
positive bacilli were suspected by the Gram staining examination.
2) If blood cultures were positive and Gram-positive bacilli were
suspected in patients with nosocomial bacteremia. 3) If the Gram
staining examination of a positive blood culture indicated the same
bacteria as was present in a previous positive blood culture ob-
tained within the past week. 4) If differentiation between GP and
GN was difﬁcult by the Gram staining examination. 5) If more than
24 h had passed after the positive blood culture alarm by the BacT/
ALERT 3D system. 6) If palliative care was being performed without
aggressive treatment for infections. 7) If patients had already died
before or on the day when the results of the Gram staining exam-
inations were performed 8) If contamination was suspected based
on the clinical ﬁndings.1.3. Diagnostic system for bacteremia and the role of the ID
physicians
At TMCH, each blood culture bottle was promptly transferred to
an in-house laboratory after blood samples were obtained either in
the emergency departments or inpatient wards, and was inserted
into the BacT/ALERT 3D system by laboratory staff members 24 h/
day. Gram staining examinations were performed on the blood in
positive blood culture bottles by laboratory staff members in charge
of microbiology from Monday to Sunday, and the results were
provided to each hospital physician. Further evaluations were
performed mainly with the MicroScan WalkAway-96 (Beckman
Coulter, Inc.; Tokyo, Japan) at the microbiology center (Miroku
Medical Laboratory Inc.). The ID physician intervened for all of the
patients with positive blood cultures on weekdays, and each case
was discussed every Wednesday with the faculty of the Depart-
ment of Infectious Disease, University of Tsukuba Hospital.
During the intervention period, Verigene system examinations
were performed from Monday to Sunday with proper ethical pro-
cesses, and the results with the judgments of the ID physicians
were reported to the physicians in charge of each patient. The
Verigene system examination was performed once for one of the
eligible positive blood culture bottles per case, unless a re-
examination was required, and the judgment regarding the selec-
tion of antimicrobial agents was facilitated by an antibiogram of the
bacteria isolated from blood or cerebrospinal ﬂuid in southern
Ibaraki prefecture in 2012 (Supplementary ﬁle 3). The ﬁnal
H. Suzuki et al. / J Infect Chemother 21 (2015) 849e856 851decisions regarding treatment were made by the physicians in
charge of each patient.
1.4. Clinical assessment and outcome measurements
As baseline characteristics, we compared the age, gender, place
of the onset of infection, co-morbidities, severity of infections,
laboratory ﬁndings (WBC and C-reactive protein) at the time when
the blood culture was obtained, the sources of infections, causative
pathogens, the duration between the initiation of incubation and
the day the conventional microbiological identiﬁcation was re-
ported and the rate of carbapenem use.
The primary outcome analyzed was the duration before the
initiation of appropriate antimicrobial therapy after obtaining
blood cultures, and the secondary outcomes were the differences
in the costs of additional antimicrobial agents, 14-day mortality
and 30-day mortality. Appropriate antimicrobial agents were
deﬁned as antimicrobial agents based on the in vitro susceptibility
testing for the causative pathogen of the bacteremia. The costs of
additional antimicrobial agents was calculated based on the
prescription cost for antimicrobial agents without conﬁrmed
in vitro susceptibility of the causative pathogens of the bacter-
emia, and the prescription cost for antimicrobial agents such as
vancomycin for methicillin-sensitive Staphylococcus spp. or anti-
pseudomonal agents, such as carbapenems, for third-generation
cephalosporin-sensitive Escherichia coli. Additional prescription
costs were calculated for the antimicrobial agents prescribed
between the day when the blood culture was obtained and the
day when the results of conventional microbiological methods
were reported.
1.5. Microbiological analysis for bacterial identiﬁcation and
antimicrobial susceptibility testing
All of the strains isolated from blood were preserved
at 80 C during the control and intervention periods. For the
strains with discrepancies in the bacterial identiﬁcation between
the Verigene system and conventional microbiological methods
or difﬁculty in the identiﬁcation by conventional microbiological
methods, a genotypic identiﬁcation was performed using a par-
tial DNA sequence analysis of the 16S rRNA gene with an ABI
PRISM BigDye Terminator Cycle Sequencing Kit v3.1 (Applied
Biosystems, Inc., Foster City, CA, USA). The genotypic results were
compared with those of each type strain of bacteria with the
Genbank database, and the highest similarity was thus applied to
make the ﬁnal identiﬁcation. A re-evaluation of the AST with a
Dry Plate (Eiken Chemical Co., Ltd., Tokyo, Japan) or E-test
(SYSMEX bioMerieux Co., Ltd., Tokyo, Japan) was performed if
strains were non-susceptible to the antimicrobial agents used for
the treatment of bacteremia analyzed by the MicroScan
WalkAway-96 or if the susceptibility of antimicrobial agents
administered was not evaluated. These additional evaluations
were basically performed after each patient's treatment, and the
results were not available during either the control or interven-
tion period.
1.6. Statistical analysis
Categorical variables were analyzed using the c2 test or Fisher's
exact test as appropriate. Continuous variables were compared
using Student's t-test or Welch's t-test based on the deviation. The
SPSS version 20 software package (IBM, Armonk, NY, USA)was used
for all analyses, and statistical signiﬁcance was deﬁned as a 2-tailed
level of signiﬁcance of p < 0.05.2. Results
During the control and intervention periods, 767 sets of blood
culture bottles (469 in the control period, 298 in the intervention
period) produced true positive signals and 239 cases (147 in the
control period, 92 in the intervention period) were considered to be
potential comparable cases (Fig. 1). In the intervention period, a
rapid diagnosis with Verigene system could not be performed in
four cases, so 88 cases (96%) were included in the ﬁnal analysis.
The performance of the Verigene system during the interven-
tion period is shown in Table 1. The median duration between the
initiation of the blood culture incubation and the reporting time of
Verigene system result was 21.7 h (IQR 18.2e26.8), and the results
were similar for the Gram-positive (20.8 h, IQR 18.4e24.6) and
Gram-negative (22.4 h, IQR 18.2e27.2) bacteria. In three cases, the
results of the Verigene system were reported to the hospital
physician the same day as the blood cultures were taken from pa-
tients. There were no cases of discordance of the bacterial identi-
ﬁcation and antimicrobial resistance between the conventional
microbiological methods and the Verigene system during the
intervention period.
The basic characteristic of the cases in the control and inter-
vention periods are summarized in Table 2. Compared with the
control period, females were slightly predominant (49% vs. 37%,
p ¼ 0.085) and hospital-onset infections were signiﬁcantly less
common (24% vs. 44%, p ¼ 0.002) during the intervention period.
The differences in co-morbidities and the severity of bacteremia
were not signiﬁcant between the two periods. Joint and vertebral
infections were prevalent during the intervention period, while
there were more cases with infective endocarditis with or without
other sites of infections during the control period (p ¼ 0.009).
Carbapenems were used for 12 patients (8%) with bacteremia
during the control period and 3 patients (3%) with bacteremia
during the intervention period.
The etiology of bacteremia between the control and the inter-
vention periods are summarized in Table 3. There was no statistical
difference between the two periods regarding speciﬁc bacteria,
including drug-resistant bacteria such as MRSA, non-fermentative
Gram-negative bacilli and third-generation cephalosporin-resis-
tant Enterobacteriaceae. There were ﬁve cases of methicillin-
resistant, coagulase-negative staphylococci (MR-CNS) bacteremia
in the control period, whereas there was no case of MR-CNS in the
intervention period.
The time-dependent rates of cases treated with antimicrobial
agents with susceptibility for each causative pathogen are
described in Fig. 2. In the intervention period, the administration of
an appropriate antimicrobial agent was signiﬁcantly earlier than
during the control period (p ¼ 0.001), and most of cases (90%; 79/
88) were treated with antimicrobial agents to which the bacteria
were susceptible by the next day (day 1) after the blood culture was
obtained.
In the intervention period, most cases with the initial inappro-
priate antimicrobial agent prescription (n¼ 15) were changed to an
appropriate agent by day 1 (9/15) or day 2 (10/15) based on the
results of the Verigene system examination. For three cases,
changes in the prescribed antimicrobial agents were made ac-
cording to the results of conventional antimicrobial susceptibility
testing and clinical response. Appropriate antimicrobial agents
were not administered to two cases in the intervention period due
to clinical improvement; one case was treated with ampicillin/
sulbactam for E. coli (ampicillin/sulbactam; MIC ¼ 16/4 mg/mL)-
associated cholangitis and another case was treated with cefozo-
pran for Achromobacter xylosoxydans (cefozopran; MIC 32 mg/mL)
bacteremia, possibly due to a peripheral catheter infection. None of
the 15 cases died during hospitalization. Three patients died within
Fig. 1. A ﬂowchart of the case selection process.
Table 1
The results of an analysis of the performance of the Verigene system for evaluating bacteremia during the intervention period.
Total GP GN
N ¼ 88 N ¼ 20 N ¼ 68
Incubation period for a positive signal obtained from blood culture bottle (hr) 13.6 (12.6e16.8) 14.0 (12.7e16.6) 13.4 (12.6e16.8)
Duration between the initiation of incubation and reporting of the Gram stain examination (hr) 19.2 (15.6e23.5) 17.6 (15.7e20.2) 19.9 (15.3e23.9)
Duration between the initiation of incubation and reporting of the Verigene system result (hr) 21.7 (18.2e26.8) 20.8 (18.4e24.6) 22.4 (18.2e27.2)
Duration between the initiation of incubation and reporting of conventional microbiological identiﬁcation (hr) 80.8 (71.8e99.4) 74.9 (70.7e115.9) 82.5 (72.9e96.1)
Number of bacterial identiﬁcations achieved by the Verigene systema 78 (88.6)b 20/20 (100) 58/68 (85.3)b
(excluding Klebsiella variicola)c 78/86 (90.7) N/A 58/66 (87.9)
Concordance rate of the bacterial identiﬁcationd 86 (100) 20/20 (100) 68 (100)
Prediction of antimicrobial resistance
Methicillin resistance/mecA analysis performede 10/10 (100) 10/10 (100) N/A
Vancomycin resistance/vanA or vanB analysis performedf 1/1 (100) 1/1 (100) N/A
Cefotaxime/ceftriaxone nonsusceptibility/blaCTX-M analysis performedg 45/45 (100) N/A 45/45 (100)
Meropenem nonsusceptibility/carbapenase gene analysis performedh 68/68 (100) N/A 68/68 (100)
All categorical data are presented as numbers (proportion, %). The continuous data are presented as medians (interquartile range).
GP Gram-positive bacteria, GN Gram-negative bacteria, N/A not applicable.
a Genotypic identiﬁcation was performed using a partial DNA sequence analysis of the 16S rRNA gene for the strains with discrepancies in the bacterial identiﬁcation
between the Verigene system and conventional microbiological methods or difﬁculty in the identiﬁcation by conventional microbiological methods.
b Achromobacter xylosoxydans (1), Bacteroides thetaiotaomicron (1), Campylobacter jejuni (1), Capnocytophaga canimorsus (1), Klebsiella variicola (2), Moraxella osloensis (1),
Salmonella spp. (2), Shewanella haliotis (1).
c Two strains of Klebsiella variicola were not detected during intervention periods with the GN panel, and were accurately detected by improved GN panels, which were
performed later.
d In one strain of Streptococcus constellatus, the Verigene system initially analyzed it as “not detected,” and it was accurately judged by re-examination, whichwas performed
soon after the ﬁrst examination.
e There were three strains of mecA-positive staphylococci.
f vanA or vanB genes were not detected.
g The analysis was performed for strains of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca and Proteus spp. There were ﬁve stains of CTX-M-positive
Enterobacteriaceae.
h blaIMP, blaKPC, blaVIM, blaNDM, blaOXA were measured, and there was one strain of IMP-positive Pseudomonas aeruginosa.
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Table 2
The characteristics of cases with bacteremia during the control and intervention periods.
Control period Intervention period P value
(n ¼ 147) (n ¼ 88)
Age (y) 72.7 (17.4) 70.2 (22.3) 0.357
Female 55 (37.4) 43 (48.9) 0.085
Hospital-onset infection 64 (43.5) 21 (23.9) 0.002
Hospital-onset infection or community-onset
healthcare-associated infection
84 (57.1) 43 (48.9) 0.227
Charlson's comorbidity index scale 2.0 (1.9) 1.6 (1.8) 0.101
Diabetes mellitus 34 (23.1) 26 (29.5) 0.275
Malignancy 27 (18.4) 12 (13.6) 0.345
Immunosuppressive drugs 5 (3.4) 4 (3.4) 0.999
Clinical severity scale 0.897
Severe sepsis 38 (25.9) 22 (25.0)
Septic shock 14 (9.5) 7 (8.0)
WBC (/mL) 11,557 (6791) 12,326 (6970) 0.406
C-reactive protein (mg/dL) 10.2 (8.6) 9.2 (7.0) 0.351
Source of infection
Urinary tract 52 (35.4) 39 (44.3) 0.213
Pulmonary 8 (5.4) 1 (1.1) 0.159
Intestine or biliary tract 11 (7.5) 11 (12.5) 0.248
Skin and soft tissue 7 (4.8) 5 (5.7) 0.767
Heart (infective endocarditis) 9 (6.1) 2 (2.3) 0.217
Joint and vertebrae 4 (2.7) 10 (11.4) 0.010
Bacteremia or catheter-related 49 (33.3) 19 (21.6) 0.074
Othersa 7 (4.8) 1 (1.1) 0.264
Duration between the initiation of incubation
and day when the results of conventional microbiological
identiﬁcation were reported (days)
3.95 (1.24) 3.84 (1.29) 0.511
Number of patients treated with carbapenems for bacteremia 12 (8.2) 3 (3.4) 0.178
All categorical data are presented as the numbers (proportion, %). Continuous data are presented as the means (standard deviation).
a Multiple sites of infections (5), subdural abscess (1), meningitis (1), mycotic aneurysm (1).
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susceptibility testing for causative bacteria during the control
period.
The data regarding the additional costs and mortality are shown
in Table 4. Compared with the control period, the additional costs
for antimicrobial agents were signiﬁcantly reduced in the inter-
vention period (3618 yen vs. 8505 yen, p ¼ 0.001). Both the cost for
antimicrobial agents against non-susceptible causative bacteria of
bacteremia (2031 yen vs. 4644 yen, p ¼ 0.013) and the cost for
unnecessary anti-MRSA agents or antipseudomonal agents (1586
yen vs. 3915 yen, p ¼ 0.042) were reduced in the interventionTable 3
Etiology of bacteremia between the control period and intervention period.
Gram-positive bacteria
Staphylococcus aureus
(methicillin-resistant S. aureus)
Coagulase negative staphylococci
(methicillin-resistant CNS)
Enterococci
Streptococci
Other Gram-positive bacteria
Gram-negative bacteria
Escherichia coli
Klebsiella spp.
Proteus spp.
(Third-generation cephalosporin-resistant E. coli, Klebsiella spp. or Proteus spp.)
SPACE, non-fermentative Gram-negative bacilli
Other Gram-negative bacteria
Polymicrobiala
All categorical data are presented as number (proportion, %).
CNS coagulase-negative staphylococci, SPACE Serratia marcescens, Pseudomonas aerugino
a The record of Gram stain examinations for blood obtained from positive blood cultures
All of the four cases had polymicrobial infections of Gram-negative bacteria and surviveperiod. The cost reduction was prominent among GP cases (2488
yen vs.11585 yen, p¼ 0.002), while the differencewas not observed
in the community-onset GN cases (3797 yen vs. 4272 yen,
p¼ 0.797). The 30-day mortality was signiﬁcantly lower during the
intervention period (3% vs. 13%, p ¼ 0.019).
3. Discussion
During this clinical trial, the Verigene system BC-GP and BC-GN
could reliably predict the causative bacteria and their antimicrobial
resistance in most cases, and the results were available in 88% ofControl period Intervention period P value
(n ¼ 147) (n ¼ 88)
19 (12.9) 9 (10.2) 0.678
10/19 (52.6) 3/9 (33.3) 0.435
6 (4.1) 1 (1.1) 0.261
5/6 (83.3) 0/1 (0) 0.286
6 (4.1) 1 (1.1) 0.261
15 (10.2) 9 (10.2) 0.999
1 (0.7) 0 0.999
43 (29.3) 31 (35.2) 0.385
15 (10.2) 12 (13.6) 0.527
4 (2.7) 2 (2.3) 0.999
5 (8.1) 4 (8.9) 0.999
32 (21.8) 17 (19.3) 0.741
2 (1.4) 6 (6.8) 0.055
4 (2.7) 0 0.3
sa, Acinetobacter spp., Citrobacter spp., Enterobacter spp., N/A not applicable.
showed one organism, however, multiple species of bacteria were ﬁnally cultivated.
d at discharge.
Fig. 2. (a) The rates of treatment with antimicrobial agents with susceptibility for each
causative pathogen of the bacteremia. (b) Reporting day of the results of the Verigene
system and conventional microbiological identiﬁcation methods after obtaining blood
cultures.
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intervention contributed to earlier initiation of treatment with an
appropriate antimicrobial agent, and led to favorable outcomes
without an increase in the carbapenem use. A decrease in the
prescribed antimicrobial agents against non-susceptible causative
bacteria and refrainment of unnecessary anti-MRSA agents or
antipseudomonal agents resulted in cost reduction in the inter-
vention period, especially among cases with Gram-positive
bacteremia.
Several important points should be considered when inter-
preting the present results. First, we used local antibiogram data,
along with the results of the Verigene system examinations, when
making the choice of antimicrobial agents during the intervention
period. While the Verigene system can identify most of theTable 4
The secondary outcomes of cases with bacteremia during the control and intervention p
Additional costs of antimicrobial agents (yen)
Gram-positive and Gram-negative bacteria
(Cost for antimicrobial agents against non-susceptible causative bacteria of bacterem
(Cost for unnecessary anti-MRSA agents or antipseudomonal agents)
Gram-positive bacteria
(Gram-positive cocci in clusters)
(Gram-positive cocci in chains)
Gram-negative bacteria (GN)
(Hospital-onset GN infection)
(Community-onset GN infection)
(Community-onset healthcare-associated GN infection)
14-day Mortality (%)
30-day Mortality (%)
All categorical data are presented as numbers (proportion, %). The continuous data are pcausative bacteria of bacteremia and their major antimicrobial
resistance for beta-lactam agents and vancomycin, we could not
obtain information regarding the resistance to other antimicrobial
agents, such as ﬂuoroquinolones. In addition, the presence of a
deﬁciency or loss of porin expression, active efﬂux pump systems,
overproduction of AmpC beta-lactamase [30], production of ESBLs
other than CTX-M ESBL [3] or mutation of penicillin-binding pro-
tein [31] were not detectable by the Verigene system. Thus, the
availability of the local antibiogram had an important role in the
decision-making regarding the choice of antimicrobial agent in this
study.
In this clinical trial, ID physicians were involved in deciding on
the treatments for all cases of bacteremia. The presence of ID
physicians is considered to be useful for the treatment of bacter-
emia [32], and the choice of antimicrobial agent was the leading
question from hospitals physicians to ID physicians according to a
recent prospective multi-countries study [33]. There is a current
need to select the antimicrobial agent based on the clinical mani-
festations and rapid testing results, including the urinary antigen
test and/or Gram stain examinations for bacteremic patients in the
acute phase, and the present study indicated the signiﬁcant assis-
tance provided by the Verigene system due to rapid availability of
bacterial identiﬁcation and prediction of antimicrobial resistance.
The most important beneﬁt of the rapid diagnostic methods,
including the Verigene system examinations, is their rapidity in
providing results. For example, there were limited clinical beneﬁts
recognized in a recent clinical trial that utilized a multiplexed
molecular method for bacteremia, which required 51 h to report
the results of the molecular method after the blood culture ob-
tained [34]. In addition, the results might not be useful if the
physician does not understand the results or change antimicrobial
agents as appropriate. Therefore, cooperation among the labora-
tory, ID physicians and the clinicians in charge of patients with
bacteremia is essential for maximizing the effectiveness of the
Verigene system examinations.
As limitations, this study was performed in Japan, where in-
fections with vancomycin intermediate S. aureus and vancomycin-
resistant enterococci were rarely encountered [35,36], but MRSA
and CTX-M-producing Enterobacteriaceae were commonly isolated
[35,37]. Thus, the current results might not be applicable in other
counties, especially in countries with a low prevalence rate of
MDRO infections [38]. In addition, matrix-assisted laser desorption/
ionization time (MALDI-TOF) has been introduced into clinical
practice as a rapid identiﬁcation method for bacteria, and a recent
study indicated that there was a reduction of the time to identiﬁ-
cation by 28 h (84 h vs. 56 h) among patients with bacteremia [39]:eriods.
Control period Intervention period P value
(n ¼ 147) (n ¼ 88)
8505 (14,274) 3618 (7623) 0.001
ia) 4644 (9975) 2031 (6038) 0.013
3915 (11,920) 1586 (5239) 0.042
11585 (17,503) 2488 (4666) 0.002
14,611 (20,449) 4498 (5891) 0.136
7989 (13,333) 477 (1510) 0.019
7057 (12,309) 3951 (8294) 0.052
10,326 (13,454) 4376 (9516) 0.092
4272 (10,591) 3797 (7908) 0.797
4450 (3869) 3010 (6051) 0.461
8 (5.4) 1 (1.1) 0.159
19 (12.9) 3 (3.4) 0.019
resented as the means (standard deviation).
H. Suzuki et al. / J Infect Chemother 21 (2015) 849e856 855the effectiveness of the Verigene system has not been clariﬁed
under such circumstances. Third, while co-morbidity and severity
were similar between both periods, hospital-onset infection was
more common in the control period and there was a difference in
the ratio of infection sites between the two periods, which may
have affected the difference in the prognosis. In addition, we did
not perform the Verigene system examination for patients with
bacteremia caused by multiple organisms or with suspected
contamination. Furthermore, we could not evaluate the necessity of
the Verigene system for each speciﬁc organism or speciﬁc place of
onset in the present trial. The accumulation of in vitro and clinical
data will be necessary to evaluate the utility of the Verigene system
for these situations.
In conclusion, the results of the Verigene Gram-positive blood
culture test and the Verigene Gram-negative blood culture test
were available for most of the cases, and the rapid diagnosis of the
causative pathogens improved the rate of administration of
appropriate antimicrobial agents without increasing the use of
carbapenems. Beneﬁts were also recognized for the antimicrobial
prescription costs and patient prognosis.
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